Overview

Long-term Efficacy and Safety of OLE LIB003 in HoFH, HeFH, and High-risk CVD Patients Requiring Further LDL-C Reduction

Status:
Enrolling by invitation

Trial end date:
2024-03-31

Target enrollment:

Participant gender:

Summary

The study is to assess the long-term safety, tolerability, and efficacy after 48 and 72 weeks with monthly (Q4W [<31 days]) dosing of subcutaneous (SC) LIB003 300 mg administered in patients with CVD or at high risk for CVD (including HoFH and HeFH) on stable diet and oral LDL-C lowering drug therapy who completed one of the LIB003 Phase 3 base studies.

Phase:

Phase 3

Details

Lead Sponsor:

LIB Therapeutics LLC

Collaborator:

Medpace, Inc.